Description: Rituximab (Rituxan® ) is a chimeric mouse/human monoclonal antibody used for treating B cell malignancy, autoimmune conditions, and graft rejection by depleting B cells from the body. This immunogenicity assay employs the bridging ELISA technique. The Rituximab immunogenicity assay employs the bridging ELISA technique. A precoated 96 well capture antibody plate is provided. Quality control and test samples are pipetted into the appropriate wells. Anti-Rituximab present in biological matrices binds the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Rituximab present in test samples. Four levels of QC samples give a qualitative reference signal which can be used to determine the level (High, Medium, Low, Negative) of anti-Rituximab antibody in the unknown samples.

Description: Rituximab is a chimeric monoclonal antibody used in the treatment of diseases characterized by abnormal or excessive B cells. Rituximab targets CD20, which is expressed on the surface of B cells, to induce apoptosis in B cells and is used in the treatment of leukemias and lymphomas, some autoimmune disorders, and organ transplant. A quantitative method for Rituximab has been developed and optimized for pharmacokinetic assessment of samples. The Rituximab ELISA kit is designed to measure free Rituximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Rituximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Rituximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Rituximab present in test samples and the concentration is calculated from the standard series.

Description: Human (Homo sapiens)

Description: Human (Homo sapiens)